hyperalgesia/atrophy

Epidemiology and suggested mechanisms involved in pediatric chemotherapy induced neuropathy: Pediatric chemotherapy induced peripheral neuropathy (CIPN) is an early (often occurring within the first three months), potentially severe long-lasting and dose limiting adverse effect of treatment in

Tissues in the genitourinary system are both androgen- and estrogen-dependent. The clitoris, vestibule, urethra, anterior vaginal wall, peri-urethral tissue, and pelvic floor are androgen-responsive. In addition, the minor vestibular glands and the major vestibular glands (Bartholin's and Skene's)

The clinical manifestation of disc degeneration and/or disc herniation can be low back pain and/or sciatica. The patterns of sensory and motor signs and symptoms that develop after neuropathy vary between individual patients with disc degeneration and/or disc herniation. The expression of these

Fibromyalgia syndrome (FMS) is a multisystemic disease, characterized by generalized chronic musculoskeletal pain. In addition, it is usually accompanied by fatigue, sleep disorders, morning stiffness, cognitive disorders, depression, anxiety and stress. Other common symptoms are back pain,

PROJECT DESCRIPTION Principal Investigator: Hajime Tokuno, MD Project Title: "Efficacy of botulinum toxin injection in reducing limb pain in patients with Complex Regional Pain Syndrome" Purpose: Complex Regional Pain Syndrome is a condition affecting anywhere from 1 to 5 million Americans including

Cachexia is a multifactorial syndrome characterized by tissue wasting, loss of body weight, particularly of lean body (muscle) mass (LBM) and to a lesser extent adipose tissue, metabolic alterations, fatigue, reduced performance status, and very often accompanied by anorexia leading to a reduced

Treatment options for patients suffering from osteoarthritis remain limited. TNF-alpha has been identified as a major pro-inflammatory component inducing and perpetuating peripheral hyperalgesia and cartilage degeneration in various preclinical studies. DLX105 is an antibody fragment of comparably

SHIATSU ADJUVANT THERAPY FOR SCHIZOPHRENIA Protocol for an Open Pilot Study 1. Background Schizophrenia is a severe, chronic mental illness that affects approximately 1% of the population worldwide. While the pharmacological treatments available have advanced considerably in the last fifty years,

This randomized controlled trial is intended to be the first in a series of trials that will assess the efficacy of drugs, which relieve neuropathic pain, on stimulus-evoked pain (here: mechanical hyperalgesia to static punctate stimuli). Most drugs in this class (e.g. Gabapentin or NMDA receptor